Publications
Detailed Information
Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: A single institution experience
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hee Seung | - |
dc.contributor.author | Kim, Jae Weon | - |
dc.contributor.author | Wu, Hong Gyun | - |
dc.contributor.author | Chung, Hyun Hoon | - |
dc.contributor.author | Song, Yong Sang | - |
dc.contributor.author | Lee, Hyo Pyo | - |
dc.contributor.author | Kang, Soon Beom | - |
dc.contributor.author | Park, Noh Hyun | - |
dc.date.accessioned | 2012-06-04T08:55:52Z | - |
dc.date.available | 2012-06-04T08:55:52Z | - |
dc.date.issued | 2010-06 | - |
dc.identifier.citation | JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH; Vol.36 3; 598-604 | ko_KR |
dc.identifier.issn | 1341-8076 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76811 | - |
dc.description.abstract | Aim: We sought to compare survival and toxicity between paclitaxel/carboplatin (TC) and doxorubicin/cisplatin (AP) for concurrent chemoradiation (CCR) in intermediate- or high-risk endometrioid endometrial cancer. Methods: The clinical data of 40 patients with intermediate- (FIGO stage IC-IIB, n = 12) or high-risk endometrioid endometrial cancer (FIGO stage IIIA-IVA, n = 28) were reviewed retrospectively between March 2000 and December 2007, who were treated with TC (n = 23, group 1) or AP (n = 17, group 2) for CCR after surgery. Results: Progression-free survival (PFS) and overall survival (OS) were not different between groups 1 and 2 (median PFS and OS; 35 vs 24 and 76 vs 39 months, respectively, P > 0.05). However, >= 6 cycles of chemotherapy improved PFS compared with 3-5 cycles of chemotherapy (51 vs 21 months, P = 0.04), suggesting that >= 6 cycles of chemotherapy was an independent prognostic factor improving PFS (adjusted HR, 0.27; 95% CI, 0.08 to 0.91; P = 0.04). Grade 3 or 4 hematological and non-hematological, especially, gastrointestinal, toxicities related with chemotherapy during CCR were more common in group 2 than in group 1, whereas there was no difference in grade 3 or 4 late complication by CCR between the 2 groups. Conclusion: These findings suggest that TC may have comparable efficacy to AP for CCR with lesser toxicity, and >= 6 cycles of chemotherapy may be more beneficial than 3-5 cycles of chemotherapy in intermediate- or high-risk endometrioid endometrial cancer. However, large-scale randomized controlled trials are needed to support these results. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL PUBLISHING, INC | ko_KR |
dc.subject | carboplatin | ko_KR |
dc.subject | cisplatin | ko_KR |
dc.subject | doxorubicin | ko_KR |
dc.subject | paclitaxel | ko_KR |
dc.subject | endometrioid endometrial cancer | ko_KR |
dc.title | Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: A single institution experience | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김희승 | - |
dc.contributor.AlternativeAuthor | 김재원 | - |
dc.contributor.AlternativeAuthor | 우홍균 | - |
dc.contributor.AlternativeAuthor | 정현훈 | - |
dc.contributor.AlternativeAuthor | 박노현 | - |
dc.contributor.AlternativeAuthor | 송용상 | - |
dc.contributor.AlternativeAuthor | 강순범 | - |
dc.contributor.AlternativeAuthor | 이효표 | - |
dc.identifier.doi | 10.1111/j.1447-0756.2010.01223.x | - |
dc.citation.journaltitle | JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH | - |
dc.description.citedreference | Kim K, 2009, J GYNECOL ONCOL, V20, P203, DOI 10.3802/jgo.2009.20.4.203 | - |
dc.description.citedreference | Hogberg T, 2008, CLIN ONCOL-UK, V20, P463, DOI 10.1016/j.clon.2008.04.001 | - |
dc.description.citedreference | Sorbe B, 2008, INT J GYNECOL CANCER, V18, P803, DOI 10.1111/j.1525-1438.2007.01094.x | - |
dc.description.citedreference | LEE HP, 2008, KOREAN J OBSTET GYNE, V51, P1411 | - |
dc.description.citedreference | *PORTEC 3, 2008, PORTEC3 | - |
dc.description.citedreference | *GOG, 2008, 209 GOG | - |
dc.description.citedreference | *RTOG, 2008, 9905GOG0194 RTOG | - |
dc.description.citedreference | Humber CE, 2007, ANN ONCOL, V18, P409, DOI 10.1093/annonc/mdl417 | - |
dc.description.citedreference | Lupe K, 2007, INT J RADIAT ONCOL, V67, P110, DOI 10.1016/j.ijrobp.2006.08.006 | - |
dc.description.citedreference | Sovak MA, 2007, INT J GYNECOL CANCER, V17, P197, DOI 10.1111/j.1525-1438.2006.00746.x | - |
dc.description.citedreference | HOGBERG T, 2007, J CLIN ONCOL, V25 | - |
dc.description.citedreference | FODA I, 2007, J EGYPT NATL CANC I, V19, P163 | - |
dc.description.citedreference | Creasman WT, 2006, INT J GYNECOL OBSTET, V95, pS105 | - |
dc.description.citedreference | Greven K, 2006, GYNECOL ONCOL, V103, P155, DOI 10.1016/j.ygyno.2006.02.007 | - |
dc.description.citedreference | Gadducci A, 2006, CRIT REV ONCOL HEMAT, V58, P242, DOI 10.1016/j.critrevonc.2005.11.002 | - |
dc.description.citedreference | Hidaka T, 2006, J OBSTET GYNAECOL RE, V32, P330, DOI 10.1111/j.1447-0756.2006.00405.x | - |
dc.description.citedreference | Mangili G, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2407-6-198 | - |
dc.description.citedreference | Michener CM, 2005, J CANCER RES CLIN, V131, P581, DOI 10.1007/s00432-005-0676-x | - |
dc.description.citedreference | Akram T, 2005, AM J OBSTET GYNECOL, V192, P1365, DOI 10.1016/j.ajog.2004.12.032 | - |
dc.description.citedreference | Kuwabara Y, 2005, JPN J CLIN ONCOL, V35, P23, DOI 10.1093/jjco/hyi003 | - |
dc.description.citedreference | Thigpen JT, 2004, J CLIN ONCOL, V22, P3902, DOI 10.1200/JCO.2004.02.088 | - |
dc.description.citedreference | Soper JT, 2004, GYNECOL ONCOL, V95, P95, DOI 10.1016/j.ygyno.2004.06.041 | - |
dc.description.citedreference | Fleming GF, 2004, J CLIN ONCOL, V22, P2159, DOI 10.1200/JCO.2004.07.184 | - |
dc.description.citedreference | Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048 | - |
dc.description.citedreference | Aapro MS, 2003, ANN ONCOL, V14, P441, DOI 10.1093/annonc/mdg112 | - |
dc.description.citedreference | Creutzberg CL, 2000, LANCET, V355, P1404 | - |
dc.description.citedreference | OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649 | - |
dc.description.citedreference | AALDERS J, 1980, OBSTET GYNECOL, V56, P419 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.